Home > Insider Trading > Filing (0001209191-22-035228)

Filing Details

Accession Number:: 0001209191-22-035228
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-06-08 19:39:33
Reporting Period:: 2022-06-06

Accepted Time:: 2022-06-08 19:39:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Biosciences Inc.	PCRX	Pharmaceutical Preparations (2834)	510619477

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1524338	Anthony Charles Laranjeira	C/O Pacira Biosciences, Inc. 5401 West Kennedy Boulevard, Suite 890 Tampa FL 33609	Chief Technical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2022-06-06	2,813	$61.37	30,789	No	4	S	Direct
Common Stock	Disposition	2022-06-08	2,521	$59.08	28,268	No	4	S	Direct
Common Stock	Disposition	2022-06-08	1,633	$60.23	26,635	No	4	S	Direct
Common Stock	Disposition	2022-06-08	516	$60.99	26,119	No	4	S	Direct
Common Stock	Disposition	2022-06-08	267	$61.98	25,852	No	4	S	Direct
Common Stock	Acquisiton	2022-06-08	9,900	$0.00	35,752	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2022-06-08	24,800	$0.00	24,800	$59.39

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
24,800		2032-06-08	No	4	A	Direct

Footnotes

Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.79 to $59.65, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 6.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.80 to $60.76, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.80 to $61.41, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.92 to $62.02, inclusive.
Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.